Scientists have uncovered a new way to curb autoimmunity — including vitiligo. A molecule recognized as essential for many functions in neurobiology is now identified as a natural "killer T-cell" controller, thereby pawing way to completely new therapies.
It's probably a good time for a recap that begins with some introspection.
Autoimmune diseases result from an overactive or misdirected immune system. There are more than 80 types of autoimmune disease, and these arise because the immune system attacks healthy tissue, mistaking it for a threat.
"Killer" T-cells are our main defence against viruses and tumours. As a major part of the adaptive immune system, T-cells scan the intracellular environment to target and destroy intruders.
In vitiligo, for reasons yet unclear, T-cells attack and destroy healthy melanocytes that produce color, thereby creating white patches on the skin.
A well-known molecule called tetrahydrobiopterin (BH4) was found to have a previously unknown role: it helps to control the growth of "killer" T cells in the immune system.
What is particularly interesting, is that the discovery concerns the control of T cell growth — as opposed to the cells' activation — when T-cells go nuts for unknown reasons and rage onto healthy cells.
It seems that T cells need BH4 to help them regulate iron and produce energy. By dialing down the amount of BH4, researchers can block T-cell proliferation in autoimmune diseases. The researchers tested some BH4 blockers on mouse models of allergies and autoimmune diseases. The experimental drugs "calmed" auto-aggressive T-cells and stopped inflammation.
The beauty of the new approach is that instead of targeting a single cytokine or class of T cells, researchers can halt proliferation in all disease-related T cells.
The finding should lead to a wide variety of medical uses, ranging from controlling autoimmune diseases, asthma, or allergies to having a new way to trigger anticancer immunity. It may take a while — but hey — we're getting there!
The leaders of the study are researchers at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna and others at the Boston Children's Hospital in Massachusetts. The journal Nature published the findings today, on November 7, 2018.
- Vitiligo and hearing loss: any connection?
In short, NO. Recent research shows no relationship between a degree of skin depigmentation and hearing loss severity in vitiligo patients. The results of this study showed tha...
- Which skin conditions can be mistaken for vitiligo?
Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...
- I have a new job - should I tell colleagues about my vitiligo?
If you are starting a new job and you are concerned about stares and questions about your skin, try a proactive approach. When the time is right and you are feeling comfortable,...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.